FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912376565> ?p ?o ?g. }

• W2912376565 abstract "TPS725 Background: T-VEC is a genetically modified, oncolytic herpes simplex virus type 1 designed to selectively replicate within tumors and produce GM-CSF to enhance systemic antitumor immune responses. Atezolizumab is a monoclonal antibody checkpoint inhibitor (CPI) that targets PD-L1. The safety of intrahepatic administration of T-VEC has been demonstrated in a prior clinical trial (NCT02509507). A previous trial of T-VEC in combination with a CPI in advanced melanoma demonstrated improved responses compared to those with a CPI alone (Puzanov et al. JCO. 2016; 34:2619-26). We hypothesize that T-VEC combined with a CPI may also be effective in other tumor types. This phase 1b, multicenter study evaluates the safety of intrahepatic injection of T-VEC in combination with IV atezolizumab in pts with TNBC or CRC with LMs. Methods: The study will enroll up to 36 pts in two parallel cohorts (18 TNBC, 18 CRC) at sites in the USA, Europe, and Australia. The primary objective is to evaluate the incidence of dose-limiting toxicities (DLTs). Secondary objectives include objective response rate, lesion-level responses in injected and uninjected tumors, progression-free survival, and overall survival. Key eligibility criteria include age ≥ 18 years, confirmed diagnosis of TNBC or CRC with LMs, ECOG performance status 0/1, adequate organ function, disease progression during or after ≥ 1 prior standard-of-care systemic therapy for metastatic disease, and ≥ 1 measurable, injectable LM. T-VEC will be given by image-guided intralesional injection of up to 4 mL of 10 6 plaque forming units (PFU)/mL on day 1 and up to 4 mL of 10 8 PFU/mL every 21 days thereafter; atezolizumab 1,200 mg IV will be given on day 1 and every 21 days thereafter. The DLT-evaluation period is the first two cycles (1 cycle = 21 days). Interim safety analysis will occur after the first 4–6 pts have become DLT evaluable. Up to six cycles of T-VEC will be given with an additional 6 cycles allowed. After cycle three, nonhepatic lesions may be injected, subject to protocol-defined criteria. The study opened for enrollment in January 2018. (NCT03256344) Clinical trial information: NCT03256344." @default.
• W2912376565 created "2019-02-21" @default.
• W2912376565 creator A5001020016 @default.
• W2912376565 creator A5005769474 @default.
• W2912376565 creator A5006886614 @default.
• W2912376565 creator A5020235177 @default.
• W2912376565 creator A5043348199 @default.
• W2912376565 creator A5049175448 @default.
• W2912376565 creator A5068059897 @default.
• W2912376565 creator A5068367016 @default.
• W2912376565 creator A5075449558 @default.
• W2912376565 date "2019-02-01" @default.
• W2912376565 modified "2023-10-03" @default.
• W2912376565 title "Phase Ib study of talimogene laherparepvec (T-VEC) injection into liver metastases (LMs) in combination with intravenous (IV) atezolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or colorectal cancer (CRC)." @default.
• W2912376565 doi "https://doi.org/10.1200/jco.2019.37.4_suppl.tps725" @default.
• W2912376565 hasPublicationYear "2019" @default.
• W2912376565 type Work @default.
• W2912376565 sameAs 2912376565 @default.
• W2912376565 citedByCount "0" @default.
• W2912376565 crossrefType "journal-article" @default.
• W2912376565 hasAuthorship W2912376565A5001020016 @default.
• W2912376565 hasAuthorship W2912376565A5005769474 @default.
• W2912376565 hasAuthorship W2912376565A5006886614 @default.
• W2912376565 hasAuthorship W2912376565A5020235177 @default.
• W2912376565 hasAuthorship W2912376565A5043348199 @default.
• W2912376565 hasAuthorship W2912376565A5049175448 @default.
• W2912376565 hasAuthorship W2912376565A5068059897 @default.
• W2912376565 hasAuthorship W2912376565A5068367016 @default.
• W2912376565 hasAuthorship W2912376565A5075449558 @default.
• W2912376565 hasConcept C121608353 @default.
• W2912376565 hasConcept C126322002 @default.
• W2912376565 hasConcept C143998085 @default.
• W2912376565 hasConcept C2775949291 @default.
• W2912376565 hasConcept C2777701055 @default.
• W2912376565 hasConcept C2780057760 @default.
• W2912376565 hasConcept C2780110267 @default.
• W2912376565 hasConcept C526805850 @default.
• W2912376565 hasConcept C530470458 @default.
• W2912376565 hasConcept C71924100 @default.
• W2912376565 hasConcept C82210918 @default.
• W2912376565 hasConceptScore W2912376565C121608353 @default.
• W2912376565 hasConceptScore W2912376565C126322002 @default.
• W2912376565 hasConceptScore W2912376565C143998085 @default.
• W2912376565 hasConceptScore W2912376565C2775949291 @default.
• W2912376565 hasConceptScore W2912376565C2777701055 @default.
• W2912376565 hasConceptScore W2912376565C2780057760 @default.
• W2912376565 hasConceptScore W2912376565C2780110267 @default.
• W2912376565 hasConceptScore W2912376565C526805850 @default.
• W2912376565 hasConceptScore W2912376565C530470458 @default.
• W2912376565 hasConceptScore W2912376565C71924100 @default.
• W2912376565 hasConceptScore W2912376565C82210918 @default.
• W2912376565 hasLocation W29123765651 @default.
• W2912376565 hasOpenAccess W2912376565 @default.
• W2912376565 hasPrimaryLocation W29123765651 @default.
• W2912376565 hasRelatedWork W2317787856 @default.
• W2912376565 hasRelatedWork W2937318637 @default.
• W2912376565 hasRelatedWork W3006236810 @default.
• W2912376565 hasRelatedWork W3010740851 @default.
• W2912376565 hasRelatedWork W3087992877 @default.
• W2912376565 hasRelatedWork W3091025601 @default.
• W2912376565 hasRelatedWork W3181102483 @default.
• W2912376565 hasRelatedWork W3189641543 @default.
• W2912376565 hasRelatedWork W4200327035 @default.
• W2912376565 hasRelatedWork W4243350270 @default.
• W2912376565 isParatext "false" @default.
• W2912376565 isRetracted "false" @default.
• W2912376565 magId "2912376565" @default.
• W2912376565 workType "article" @default.